Search

Displaying results 1081 - 1090 of 2420 in total
  1. Drug

    Benzgalantamine

    go.drugbank.com/drugs/DB19353
    ApprovedInvestigational

    Benzgalantamine is a prodrug of galantamine. Gastrointestinal adverse effects are the most frequently reported side effects in patients undergoing treatment with cholinesterase inhibitors, including galantamine, and are often a reason fo...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  2. Drug

    Hydrastine

    go.drugbank.com/drugs/DB19354
    Experimental

    Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Substrates
  3. Drug

    Umbralisib

    go.drugbank.com/drugs/DB14989
    ApprovedInvestigationalWithdrawn

    Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with rituximab (an anti-CD20 drug), either alone or in combination with chemotherapy. Unfortunately, many patients experience a relapse o...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  4. Drug

    Brepocitinib

    go.drugbank.com/drugs/DB15003
    ApprovedInvestigational

    Brepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults. It inhibits TYK2- and JAK1-mediated cytokine signaling, blocking phosphorylation of signal transducers and activat...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  5. Drug

    Gefapixant

    go.drugbank.com/drugs/DB15097
    Approved

    It has been estimated that 5-10% of adults globally suffer from chronic cough, which is defined as a cough lasting longer than eight weeks. A subset of these patients remain symptomatic despite thorough investigation and treatment, terme...

    Categories: P-glycoprotein substrates
  6. Drug

    Vamorolone

    go.drugbank.com/drugs/DB15114
    ApprovedInvestigational

    Vamorolone is a novel and fully synthetic glucocorticoid developed by Santhera Pharmaceuticals. It is used to manage inflammation and immune dysregulation in patients with Duchenne muscular dystrophy (DMD), a neuromuscular disorder chara...

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 Substrates
  7. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [A261120] Pozelimab is a human, monoclonal immunoglobulin G4<sup>P</sup> antibody against the terminal complement protein C5.

  8. Drug

    Olorofim

    go.drugbank.com/drugs/DB15245
    Investigational

    Olorofim is under investigation in clinical trial NCT03340597 (Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects).

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 Inducers
  9. Drug

    Avutometinib

    go.drugbank.com/drugs/DB15254
    ApprovedInvestigational

    Avutometinib is a small molecule kinase inhibitor targeted against RAF/MEK1, key regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. The MAPK pathway is implicated in variety of cancers, playing a key role in tumor cell proliferation, diff...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  10. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease. Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Afri...